Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy
Transgender Health · 01.12.2024 · 9 (6) · 463-465
DOI: 10.1089/trgh.2023.0209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transgender Health, online erschienen am 16.12.2024. Verfasst von Micol S Rothman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Auror…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5–30 mg every 2 weeks or 2–10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines. Our review indicates that 5 mg weekly or lower should be prescribed when initiating injectable estrogens to avoid supraphysiologic E2 levels.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.
- Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital-Harvard Medical School, Boston, Massachusetts, USA.
- Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
- Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
ORCID-Profile: Ole-Petter R Hamnvik, Sean J Iwamoto
Zitieren
APA
Rothman, M. S., Hamnvik, O. R., Davidge-Pitts, C., Safer, J. D., Ariel, D., Tangpricha, V., Abramowitz, J., Soe, K., Sarvaideo, J., Kelley, C., Irwig, M. S., & Iwamoto, S. J. (2024). Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy. Transgender Health, 9(6), 463-465. https://doi.org/10.1089/trgh.2023.0209
Vancouver
Rothman MS, Hamnvik OR, Davidge-Pitts C, Safer JD, Ariel D, Tangpricha V, et al. Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy. Transgender Health. 2024;9(6):463-465. doi:10.1089/trgh.2023.0209
BibTeX
@article{Rothman2024,
author = {Rothman, Micol S and Hamnvik, Ole-Petter R and Davidge-Pitts, Caroline and Safer, Joshua D and Ariel, Danit and Tangpricha, Vin and Abramowitz, Jessica and Soe, Kyaw and Sarvaideo, Jenna and Kelley, Carly and Irwig, Michael S and Iwamoto, Sean J},
title = {Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy},
journal = {Transgender Health},
year = {2024},
volume = {9},
number = {6},
pages = {463--465},
doi = {10.1089/trgh.2023.0209}
}
EUVIMED